by Monica Gerson
Analyst Raj Mehra of Auriga USA maintains his “buy” rating on United Therapeutics (NASDAQ: UTHR), while raising his estimates for the company. The target price for UTHR has been raised from $54 to $70.

According to Auriga USA, United Therapeutics’s Tommy G Thompson Joins the Board Tyvaso has been gaining new as well as switched-over clients from other competitors’ drugs, driven by better compliance and convenience. UTHR is expected to get the approval for Tyvaso in the EU during the first half of 1Q10, the analyst says.

Trials on United Therapeutics’ oral Treprostinil are continuing and the results are expected before this year-end. Positive data from this trial will add significant upside to UTHR’s earnings, the analyst adds. Auriga USA has raised its EPS estimates for 2009 and 2010 from $0.69 to $0.73 and from $1.54 to $1.98, respectively.

If you enjoyed this post then Subscribe to Savvy Investor via RSS